RxDoctor Payments Data

Gene Kim, MD

Clinical Cardiac Electrophysiology · Torrance, CANPI 1194732925

Payments from drug & device makers

$25,141in general payments, 2019–2025

Across 417 payments — averaging $60.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$19K
  • Medtronic$2K
  • Novartis$611
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$496
  • Johnson & Johnson$352
  • AstraZeneca$293
  • plus $2K from 28 others

What the payments were for

  • Speaking & faculty fees$16,96967%
  • Travel & lodging$410%
  • Food & beverage$8,12432%
  • Education$70%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,141 in reported general payments places this provider in the 35th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$292,661
Medicare patients
1,364
Services billed
4,930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban890$997,355
XareltoRivaroxaban175$236,321
EntrestoSacubitril/Valsartan130$131,408
MultaqDronedarone Hcl19$33,646
Repatha SureclickEvolocumab23$16,331
JardianceEmpagliflozin14$13,568
Mexiletine Hcl118$11,319
FarxigaDapagliflozin Propanediol12$10,858
Praluent PenAlirocumab12$9,430
Flecainide Acetate186$9,051
Amiodarone Hcl289$6,630
PradaxaDabigatran Etexilate Mesylate11$6,055
Metoprolol Succinate387$5,776
Dabigatran EtexilateDabigatran Etexilate Mesylate15$4,572
Losartan Potassium236$3,104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$202$997,355890 claims
Johnson & JohnsonXarelto$352$236,321175 claims
NovartisEntresto$611$131,408130 claims
Sanofi-aventis U.S. LLCMultaq$182$33,64619 claims
Boehringer IngelheimJardiance, Pradaxa$188$19,62325 claims
AstraZenecaFarxiga$293$10,85812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →